A breakthrough for brain tumor drug development

(MicroMatrices) Glioblastoma is a devastating disease with poor survival stats due in part to a lack of preclinical models for new drug testing. To address these challenges a multidisciplinary team of researchers have developed a human relevant 3D model containing tumor and normal cells and a platform for accurate drug efficacy measurements. An experimental therapy doxorubicin (DOX) was tested and found to be more active in the model than the existing therapy.

Source: EurekAlert! - Cancer - February 5, 2019 Category: Cancer & Oncology Source Type: news